Abstract
Purpose: :
To compare the 1-year incidence rates of dry eye in OAG and OH patients newly treated with LAT or TRAV-Z.
Methods: :
This retrospective analysis of information in the Pharmetrics database included patients with any OAG or OH diagnosis within 3 months of the first (index) prescription for LAT or TRAV-Z monotherapy. Patients were excluded if they had a LAT or TRAV-Z prescription within 6 months pre-index or if they had a diagnosis of dry eye (ICD-9-CM codes: 370.33, 375.15, 710.2; CPT: 68760, 68761) within 3 months pre-index. Time to incidence of dry eye during the first year post-index period was estimated using a composite endpoint: a post-index dry eye-related diagnosis identified by ICD-9-CM code OR a post-index prescription for Restasis.
Results: :
2996 patients were identified on index monotherapy (LAT, 2348; TRAV-Z, 648). The mean age was ≈65 years in both groups. Over 1 year, 5.6% (132/2348) of LAT and 7.8% (51/648) of TRAV-Z patients were identified with dry eye or were prescribed Restasis (P=0.0367; log-rank test).
Conclusions: :
The retrospective analysis of a large prescription database revealed that OAG and OH patients newly treated with LAT monotherapy were statistically significantly less likely to develop dry eye during the first year post-index period versus newly treated TRAV-Z patients.
Keywords: clinical (human) or epidemiologic studies: outcomes/complications